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Background: Cross-sectional studies have noted that subjects with diabetes have
lower lung function than non-diabetic subjects. We conducted this analysis to
determine whether diabetic subjects have different rates of lung function change
compared with non-diabetic subjects.
Methods: We conducted a nested case-control analysis in 352 men who developed
diabetes and 352 non-diabetic subjects in a longitudinal observational study of aging
in men. We assessed lung function among cases and controls at three time points:
Time0, prior to meeting the definition of diabetes; Time1, the point when the
definition of diabetes was met; and Time2, the most recent follow-up exam.
Results: Cases had lower forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) at all time points, even with adjustment for age, height, weight, and
smoking. In multiple linear regression models adjusting for relevant covariates,
there were no differences in rates of FEV1 or FVC change over time between cases
and controls.
Conclusions: Men who are predisposed to develop diabetes have decreased lung
function many years prior to the diagnosis, compared with men who do not developElsevier Ltd. All rights reserved.
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A.A. Litonjua et al.1584diabetes. This decrement in lung function remains after the development of
diabetes. We postulate that mechanisms involved in the insulin resistant state
contribute to the diminished lung function observed in our subjects.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Various lung function abnormalities have been
described in type 1 diabetic subjects [reviewed in
Sandler1]. For example, some type 1 diabetic
subjects have reduced lung volumes, reduced
elastic recoil, and reduced diffusing capacity.
These observations have not been consistently
confirmed possibly because of inadequate control
of smoking in many of these studies. 1 Although few
studies have been conducted in type 2 diabetic
subjects, the weight of the evidence appears to
point to lower lung function indices in these
subjects compared with non-diabetic subjects.
Furthermore, because the prevalence of diabetes
is increasing, with type 2 diabetes accounting for
90–95% of all cases,2 it is important to determine
whether these lung function changes also occur in
type 2 diabetes, since this may potentially have an
impact on prognosis and disease management.
Three cross-sectional studies have found lower lung
function in subjects with type 2 diabetes compared
with non-diabetic subjects,3–5 whereas one did not
find any difference.6 However, the question of
whether type 2 diabetic subjects have greater lung
function declines compared with non-diabetic
subjects remains unanswered. Clinical trials of
inhaled insulin suggest that, at least in the very
short term, diabetic subjects do not experience
great changes in their lung function.7,8 Only two
studies from the same research group have re-
ported longitudinal lung function changes in type 2
diabetic subjects. Lange et al.9 found that subjects
who developed diabetes during a 5-year period of
follow-up had the steepest declines in lung function
compared with non-diabetic subjects, whereas
those who had diabetes at the beginning of the
period of observation did not have significantly
greater declines in lung function compared with
non-diabetic subjects. Their follow-up study over
15 years did not detect any differences in lung
function decline between diabetics and non-dia-
betics.10
In order to further clarify the relationship
between diabetes and lung function, we conducted
an analysis of lung function and lung function
decline in a cohort of men who have participated in
a longitudinal study of normal aging. The long-
itudinal nature of our cohort allowed us to examinethe association between lung function and diabetes
in the periods prior to, and after the recognition of
the disease, and to compare the rates of change in
lung function between diabetic subjects and non-
diabetic subjects.Methods
Population and study sample
The Normative Aging Study is a longitudinal study
of aging established by the Veterans Administration
in 1961.11 The initial cohort of study subjects
consisted of 2280 community-dwelling men from
the Greater Boston area who were 21–80 years of
age at the time of entry into the study between
1961 and 1969. Subjects were health screened at
entry and were excluded if they had any ante-
cedent chronic medical conditions, including hy-
pertension, diabetes mellitus, heart disease,
cancer, cirrhosis, peptic ulcer disease, gout, asth-
ma, chronic bronchitis, or chronic sinusitis. Since
entry, volunteers have reported for periodic exam-
inations every 3–5 years, each consisting of a
uniform medical history and physical examination,
along with blood and urine tests, and spirometry.
Details of this cohort have been published pre-
viously.12,13 Participation in this study has been
approved by the Human Studies Subcommittee of
the Research and Development Committee, V.A.
Medical Center, Boston, MA.Study design and study sample
A nested case-control design was utilized. Cases
and controls were selected from 1433 eligible
subjects who had information regarding diabetes
diagnosis, use of diabetic medications, and fasting
blood glucose levels. Cases were defined as having
diabetes if they met one or more of the following
criteria: (1) A doctor’s diagnosis of diabetes
mellitus; (2) use of oral diabetic medication; (3)
use of insulin; or (4) a fasting blood glucose of
X7mmol/L. Controls were selected from among
those with none of the above and a fasting blood
glucose of o6.1mmol/L, and were matched to
cases by age (within 3 years) and date of exam at
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Only subjects who had at least 3 exams with lung
function data (at least one exam prior to meeting
the case definition and at least one exam after
meeting the case definition) were included in this
analysis.
Three time points were identified for the
analysis. The exam at which the subject met the
case definition for diabetes was designated as T1.
The earliest exam with lung function data prior to
T1 was designated as T0, and the last exam after T1
was designated as T2. Two time periods were
defined: T0–T1 was the period prior to recognition
of diabetes, and T1–T2 was the period after.Measurement of blood glucose
Blood glucose levels were measured after an
overnight fast. From the beginning of the study
through January 1970, serum glucose levels were
determined by standard manual methods.14 There-
after, automated methods were used, with some
changes over time in both the equipment (Techni-
con Auto-analyzer; Technicon Instruments Corp.,
Tarrytown, NY, from 1970 to 1973; Technicon AA II
after 1973) and the specific assay used (the
ferricyanide method, followed by a modified
neocuproine method, and finally, the glucose
oxidase method). Although these changes were
not systematically evaluated at the time they were
instituted, retrospective evaluation of the most
important change, from manual to automated
methods, suggested that glucose values were fairly
consistent through this transition.15Spirometry and lung function decline
Spirometry was performed in standard fashion as
previously described12,13 using a water-filled survey
spirometer (Collins 8-L; Warren E. Collins, Brain-
tree, MA, USA), and adhering to American Thoracic
Society standards.16 Each subject made up to eight
forced vital capacity maneuvers to obtain three
acceptable curves according to predefined criteria,
and standard methods were used to obtain the
forced vital capacity (FVC) and the forced expira-
tory volume in 1 s (FEV1). The largest value of the
three maneuvers for either measure (not necessa-
rily from the same curve) was used for this analysis.
All values were corrected to body temperature and
pressure saturated with water vapor (BTPS).
Lung function change (DFEV1/year and DFVC/
year) was defined as lung function (in L for FEV1 and
FVC) at the beginning of the time period minus lung
function at the end of the period, divided by thenumber of years between observations; thus,
positive values correspond to a decline in lung
function over time.
Statistical analysis
To assess the association of each variable with
cross-sectional lung function (FEV1, FVC, and FEV1/
FVC ratio, percent of predicted values) at each
time point, univariate analyses were carried out
utilizing t-tests for continuous variables and w2-
tests for categorical variables. Multiple linear
regression models for lung function were then
fitted for each time point that included age,
height, smoking status, and diabetes status. Be-
cause weight at each time point was different for
the cases and controls, multiple linear regression
models were also fitted which included weight to
determine if this variable was associated with lung
function differences among the cases and controls.
For lung function change, multiple linear regres-
sion models were fitted with FEV1/year and FVC/
year as the dependent variables. The independent
variables included age at the beginning of the
period, height, smoking status, and diabetes
status. Separate multiple linear regression models
were then fitted with weight and change in weight
to determine if these were associated with lung
function change. Additional models were fitted
with baseline lung function level at the beginning
of the relevant time period, in addition to the other
variables described above. All analyses were con-
ducted using the SAS statistical software package
(SAS Institute, Inc., Cary, NC).Results
Subject characteristics
A total of 352 cases and 352 controls were
identified for this analysis. Among the cases, 195
men met the definition of a case by the fasting
blood glucose criterion alone, while 157 cases were
included for a combination of having elevated
fasting blood glucose and a doctor’s diagnosis
(n ¼ 52); having elevated fasting blood glucose
and being on a diabetic medication (n ¼ 2); and
having all three criteria (n ¼ 103). The median
time of follow-up for T0–T1 was 13.6 years
(range ¼ 2.6–30.7 years), and for T1–T2 was 11.9
years (range ¼ 2.0–29.8 years). Characteristics of
the cases and controls are shown in Table 1. At time
T0, prior to meeting the diabetes definition, age,
height, and smoking status did not differ among
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Figure 1 (a) Decrements in FEV1 (in mL) among cases
compared with controls at all time points, stratified by
smoking status. Values are from b’s and 95% CI obtained
from linear regression models adjusted for age, height,
and weight, and stratified by smoking status. (b)
Decrements in FVC (in mL) among cases compared with
controls at all time points, stratified by smoking status.
Values are from b’s and 95% CI obtained from linear
regression models adjusted for age, height, and weight,
and stratified by smoking status.
A.A. Litonjua et al.1586cases and controls. However, cases had higher
fasting blood glucose levels and were also heavier
than controls. At times T1 and T2, the differences
between cases and controls with respect to fasting
blood glucose and weight remained. At T1, smoking
differed between cases and controls, largely due to
the greater number of cases who switched from
current smokers to former smokers, but this
difference was not significant at T2.Cross-sectional lung function analysis
Cases had significantly lower lung function values at
all time points compared with controls, because
smoking may confound the relationship between
diabetes and lung function, we performed analyses
stratified by smoking status. Because there were no
significant differences among current and former
ARTICLE IN PRESS
Table 2 Multiple linear regression models for lung function change/year.
T0–T1 P-value T1–T2 P-value
b (SE) b (SE)
DFEV1: mL/year
Intercept 131.2 (55.5) 0.02 86.2 (65.3) 0.2
Age 1.2 (0.2) 0.0001 0.6 (0.3) 0.02
Smoking status
Never — —
Current 9.7 (4.6) 0.03 11.8 (6.5) 0.07
Former 0.3 (4.6) 0.9 3.0 (5.1) 0.6
Diabetic 1.1 (3.7) 0.8 1.1 (4.5) 0.8
Model R2 0.10 0.07
DFVC: mL/year
Intercept 206.3 (57.7) 0.0004 81.3 (63.7) 0.2
Age 1.4 (0.2) 0.0001 1.1 (0.3) 0.0001
Smoking status
Never — —
Current 12.6 (4.7) 0.008 14.6 (6.4) 0.02
Former 4.5 (4.8) 0.3 7.5 (4.9) 0.1
Diabetic 3.7 (3.8) 0.3 05.4 (4.4) 0.2
Model R2 0.14 0.09
All models additionally adjusted for baseline height and weight.
Ventilatory function and diabetes 1587smokers, we combined them into the group of ever
smokers. In multiple linear regression models
adjusting for age, height, and weight, cases were
seen to have lower FEV1 (Fig. 1(a)) and FVC (Fig.
1(b)) at all time points, however, these decrements
only reached statistical significance among the ever
smoking group.Longitudinal lung function decline
Results of multiple regression models for change in
lung function over time are shown in Table 2. There
were no significant differences in yearly change in
FEV1 among cases and controls, for the two time
periods of interest after adjustment for covariates.
Based on the models in Table 2, subjects who
developed diabetes only had about a 1.1mL/year
greater decline in FEV1 compared with subjects
who did not develop diabetes, both in the period
prior to and after the recognition of diabetes. For
yearly FVC change, cases had 3.7 and 5.4mL/year
greater declines compared with controls in the 2
periods of interest, respectively. When pack-years
of smoking was substituted for smoking status in
the models in Table 2, there results were un-
changed. Additionally, we performed analyses
stratified by smoking status but we did not findany significant decline in lung function among
diabetics, whether or not they smoked.
Prior to meeting the definition of diabetes, aside
from having greater baseline weight, cases had
greater weight gain than controls: cases gained a
mean (7SD) of 3.73 (78.09) kg while controls
gained 1.36 (76.09) kg, Po0:0001. After meeting
the case definition for diabetes, from T1 to T2,
cases lost a mean of 0.18 (76.68) kg and controls
gained a mean of 0.41 (76.09) kg, but this
difference was not statistically significant
(P ¼ 0:2). When weight change for the particular
period was substituted for baseline weight in the
multiple regression models in Table 2, no changes in
the effect of being diabetic on yearly lung function
change was observed.Discussion
This study on middle aged to older men confirms
previous cross-sectional findings that lung function
(FEV1 and FVC, but not FEV1/FVC ratio) in type 2
diabetic subjects is decreased compared with non-
diabetic subjects, controlling for relevant covari-
ates. This decreased lung function is present many
years before the subjects are recognized as having
diabetes mellitus. We also found that there is no
ARTICLE IN PRESS
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between cases and controls, either in the period
prior to recognition of diabetes or in the period
after recognition of the disease.
Previous studies have also found diminished lung
function among type 2 diabetic subjects. Both in
the Copenhagen City Heart Study3 and in the
Fremantle Diabetes Study,4 lung function among
diabetic subjects was diminished when compared
with lung function among controls. More recently,
Walter et al.,5 analyzed data on 3254 participants
of the Framingham Offspring Cohort and found that
both the diagnosis of diabetes and an elevated
fasting blood glucose were associated with lower
than predicted levels of pulmonary function.
Similarly, a cross-sectional study of 3911 British
women also found an association between low lung
function and both a measure of insulin resistance
and type 2 diabetes.17 These decrements in lung
function also appear to be present among children
with established diabetes.18 Our results confirmed
these previous studies and found that lung function
in diabetic subjects in our cohort was diminished
when compared with non-diabetic subjects, even
after adjusting for age, smoking status, height, and
weight.
Our study documents diminished lung function
many years (median time ¼ 13:6 years) prior to the
recognition of diabetes. Two recent studies from
the same group19,20 have also found that the risk for
developing diabetes is inversely related to prior
lung function. Additionally, it appears that low lung
function among diabetics is also an independent
predictor of all-cause mortality.21 The decreased
lung function observed in both type 1 and type 2
diabetic subjects has commonly been explained by
the mechanism of glycosylation of proteins such as
collagen in the lungs and chest wall,22 the
postulated process by which hyperglycemia leads
to development of long-term diabetic complica-
tions in other organs.23,24 This glycosylation results
in irreversible collagen cross-linking, rendering the
collagen less susceptible to proteolysis than native
collagen, and leading to accumulation of collagen
in lung connective tissue.25 This process is likely to
be chronic, and may occur even in non-diabetic
subjects who have hyperglycemia.3 However, this
glycosylation process occurs in the early stages of
diabetes when hyperglycemia is most pronounced
and may decelerate, reaching a new equilibrium at
a lower turn-over rate of collagen.9,22 Thus, while
this mechanism may explain the greater decrement
in lung function in diabetic subjects seen around
the time of their diagnosis as reported by Lange et
al.,9 it does not fully explain the diminished lung
function of our cases at T0, many years prior tobecoming diabetic, where the level of glycemia
among cases was only mildly elevated when
compared with controls (Table 1). Another poten-
tial mechanism that may explain the findings of
decreased lung function is decreased muscle
strength in diabetic subjects. In a previous analysis
on this cohort,26 we had shown that decreased
skeletal muscle weakness (as measured by handgrip
strength) was associated with an insulin resistant
state. This decreased muscle strength was present
many years prior to the recognition of the insulin
resistant state.
It is known that at least three factors determine
lung function at a particular point in adult life: (1)
the maximally attained level of lung function; (2)
the onset of decline of lung function (or alterna-
tively, the duration of the plateau phase); and (3)
the rate of decline of lung function27 (21). It is
generally accepted that lung function reaches a
peak sometime around the ages of 20 and 25
years.28,29 In healthy, non-smoking individuals, a
phase follows wherein there is little or no change in
lung function (the plateau phase),30,31 although
lung function can continue to increase into the
fourth decade.27,29 This plateau phase likely lasts
until the ages of 30–35 years for most people,29,30
after which a period of lung function decline
ensues. Thus, since the mean age of our cases at
T0 was 43.178.1 years, it is likely that the
diminished lung function among cases at T0 was
due to either a lower maximally attained lung
function or a lack of a plateau phase. We, there-
fore, postulate that other mechanisms, in addition
to glycosylation of collagen, may be operating. It is
conceivable that these subjects may be predis-
posed to developing both low lung function and
diabetes. In prior analyses on non-diabetic subjects
in our cohort, we found that lower lung function
was associated with a state of insulin resistance (as
measured by fasting insulin levels and the fasting
insulin resistance index), both longitudinally32 and
cross-sectionally.33 The finding by Lange et al.3 of
an inverse relationship between fasting glucose
levels and lung function among non-diabetic sub-
jects is also consistent with this. Furthermore, the
cellular mechanisms underlying the insulin resistant
state may also explain the observed relationship
between low lung function with either cardiovas-
cular disease34–36,40 or all-cause mortality21,37 in
many epidemiologic studies.
While the exact mechanisms by which a state of
insulin resistance leads to low lung function
remains to be elucidated, it is becoming recognized
that two hormones that may be involved in path-
ways of insulin resistance and glucose intolerance
states—leptin and resistin—may have effects on
ARTICLE IN PRESS
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39,41,42 As more research into insulin resistance
states uncover these complicated pathways, it is
likely that mechanisms to explain epidemiologic
findings such as ours will come to light.
In this analysis, we controlled for covariates that
have been known to affect lung function level, such
as age, height, and cigarette smoking, and we also
controlled for weight. However, as with many
epidemiologic studies, residual confounding of
these variables, in particular smoking, may affect
the results. Thus, we conducted our analyses
stratified by smoking status. Diabetics who were
lifelong non-smokers had lower lung function at all
time points compared with controls (Fig. 1(a) and
(b)), although this did not reach statistical sig-
nificance after controlling for covariates, because
of the small sample size. Cases who were ever-
smokers, on the other hand, had significantly lower
lung function than ever-smoking controls, suggest-
ing that there may be an interaction between
smoking and the propensity for diabetes. When we
tested for interactions between smoking and
diabetes, however, we did not find a significant
interaction (all P values for interaction40.05), and
this may have been due to the lack of power in our
study. Nevertheless, this might be an avenue for
future studies in cohorts with adequate numbers of
smoking and non-smoking diabetics.
A selection bias may arguably explain our results,
wherein only the most healthy subjects who were
at risk for diabetes completed the lung function
testing, thus showing no differences in lung func-
tion declines over time compared with non-diabetic
subjects. A review of our subject selection showed
that 439 subjects met the diabetes criteria at some
point during their follow up in the cohort. Twenty-
five (5.7%) of these 439 were excluded because
they met the criteria at the time of entry, three
(0.7%) had no lung function data at all, 39 (8.9%)
met the diabetes criteria at their last follow-up
visit, and 20 (4.6%) subjects met the criteria, but
there were no controls that could be matched to
them. In all, 87 subjects were excluded, and a
comparison of their characteristics and available
lung function data with the 352 diabetic subjects
who were in the study showed no significant
differences (data not shown). Thus, although we
cannot entirely rule this out, it is unlikely that
selection bias could have played a large role in our
study.
We did not find a significantly different yearly
change in FEV1 nor FVC among diabetic subjects
compared with controls, either before or after
being recognized as diabetic subjects. We used
linear regression modeling in our analyses. Whenwe performed a repeated measures analysis in-
corporating all the lung function observations
between T0 and T2, we obtained almost identical
estimates for the change in lung function among
diabetics. Our results are also consistent with the
only other longitudinal study of lung function in
type 2 diabetes, which used random effects
modeling and which followed both diabetics and
non-diabetics for 15 years and did not find a
difference in their rates of decline in lung function.
Because of the small numbers in subgroups, we
were unable to perform any meaningful analyses
of the effect of treatment (i.e. insulin vs. oral
hypoglycemic drugs) on the decline in lung func-
tion.
There is some controversy regarding the need to
control for baseline level of lung function when
investigating the rate of change in these para-
meters. We present our analyses without control-
ling for baseline lung function. When we controlled
for baseline level, the parameter estimates (b) for
DFEV1/year increased to 0.0039 (P ¼ 0:3) and
0.0055 (P ¼ 0:2) for T0–T1 and T1–T2, respectively,
but retained non-significant P-values. The para-
meter estimates for DFVC/year increased to 0.0067
(P ¼ 0:07) and 0.0098 (P ¼ 0:02) for the 2 time
periods of interest, when we controlled for FVC at
the beginning of the respective time periods.
However, since both lung function parameters were
significantly different between cases and controls
at both T0 and T1, it is likely that these increased
estimates for lung function declines, when control
for baseline lung function is done, represent the
phenomenon of regression to the mean.40 In any
event, the magnitude of these declines, even for
DFVC/year, remains small and of uncertain clinical
significance in this population.
In summary, subjects who are destined to
develop diabetes have lower FEV1 and FVC values
many years prior to becoming diabetic, compared
with age-matched subjects who do not develop
diabetes. However, we did not find any differences
in FEV1 declines between diabetic subjects and
controls. We postulate that mechanisms involved in
the insulin resistant state may be responsible for
predisposing individuals to a lower maximal at-
tained lung function or to an early initiation of the
decline in lung function.References
1. Sandler M. Is the lung a
’ ’
target organ’’ in diabetes mellitus?
Arch Internal Med 1990;150:1385–8.
2. Williamson DF, Vinicor F, Bowman BA. Centers for Disease
Control and Prevention Primary Prevention Working Group.
ARTICLE IN PRESS
A.A. Litonjua et al.1590Primary prevention of type 2 diabetes mellitus by lifestyle
intervention: implications for health policy. Ann Internal
Med 2004;140:951–7.
3. Lange P, Groth S, Kastrup J, et al. Diabetes mellitus, plasma
glucose and lung function in a cross-sectional population
study. Eur Respir J 1989;2:14–9.
4. Davis TME, Knuiman M, Kendall P, et al. Reduced pulmonary
function and its associations in type 2 diabetes: the
Fremantle Diabetes Study. Diab Res Clin Prac
2000;50:153–9.
5. Walter RE, Beiser A, Givelber RJ, et al. Association between
glycemic state and lung function: the Framingham Heart
Study. Am J Respir Crit Care Med 2003;167:911–6.
6. Barrett-Connor E, Frette C. NIDDM, impaired glucose
tolerance, and pulmonary function in older adults: the
Rancho Bernardo Study. Diab Care 1996;19:1441–4.
7. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled
human insulin in type 1 diabetes mellitus: a randomized
proof-of-concept study. Lancet 2001;357:331–5.
8. Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human
insulin treatment in patients with type 2 diabetes mellitus.
Ann Internal Med 2001;134:203–7.
9. Lange P, Groth S, Mortensen J, et al. Diabetes mellitus and
ventilatory capacity: a five year follow-up study. Eur Respir J
1990;3:288–92.
10. Lange P, Pamer J, Schnohr P, Jensen G. Copenhagen City
Heart Study: longitudinal analysis of ventilatory capacity in
diabetic and nondiabetic adults. Eur Respir J 2002:1406–12.
11. Bell B, Rose CL, Damon D. The Normative Aging Study: an
interdisciplinary and longitudinal study of health and aging.
Aging Hum Dev 1972;3:5–17.
12. Sparrow D, O’Connor GT, Colton T, et al. The relationship of
nonspecific bronchial responsiveness to the occurrence of
respiratory symptoms and decreased levels of pulmonary
functions. The Normative Aging Study. Am Rev Respir Dis
1987;135:1255–60.
13. O’Connor G, Sparrow D, Taylor D, et al. Analysis of dose-
response curves to methacholine. An approach suitable for
population studies. Am Rev Respir Dis 1987;136:1412–7.
14. Folin O, Wu H. A system of blood analysis. Supplement 1. A
simplified and improved method for determination of sugar.
J Biol Chem 1920;41:367–74.
15. Cassano PA, Rosner B, Vokonas PS, et al. Obesity and body
fat distribution in relation to the incidence of non-insulin-
dependent diabetes mellitus. A prospective cohort study of
men in the Normative Aging Study. Am J Epidemiol
1992;136:1474–86.
16. American Thoracic Society. Standardization of spirome-
try—1987 update. Am Rev Respir Dis 1987; 136:1285–98.
17. Lawlor DA, Ebrahim S, Davey Smith G. Associations of
measures of lung function with insulin resistance and type 2
diabetes: findings from the British Women’s Heart and
Health Study. Diabetologia 2004;47:195–203.
18. Cazzato S, Bernardi F, Salardi S, et al. Lung function in
children with diabetes mellitus. Pediatr Pulmonol
2004;37:17–23.
19. Engstro¨m G, Janzon L. Risk of developing diabetes is
inversely related to lung function: a population-based
cohort study. Diabet Med 2002;19:167–70.
20. Engstro¨m G, Hedblad B, Nilsson P, Wollmer P, Berglund G,
Janzon L. Lung function, insulin resistance and the incidence
of cardiovascular disease: a longitudinal cohort study. J
Internal Med 2003;253:574–81.
21. Davis WA, Knuiman M, Kendall P, Grange V, Davis TME.
Glycemic exposure is associated with reduced pulmonaryfunction in type 2 diabetes: the Fremantle Diabetes Study.
Diabetes Care 2004;17:752–7.
22. Cavan DA, Parkes A, O’Donnell MJ, Freeman W, Cayton RM.
Lung function and diabetes. Respir Med 1991;85:257–8.
23. Kohn RR, Schnider SL. Glucosylation of human collagen.
Diabetes 1982;31:47–51.
24. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosyla-
tion and the pathogenesis of diabetic complications. Ann
Internal Med 1984;101:527–37.
25. Ofulue F, Thurlbeck WM. Experimental diabetes and the
lung. II. In vivo connective tissue metabolism. Am Rev Respir
Dis 1988;138:284–9.
26. Lazarus R, Sparrow D, Weiss ST. Handgrip strength and
insulin levels: Cross-sectional and prospective associations
in the Normative Aging Study. Metabolism 1997;46:1266–9.
27. Weiss ST, Ware JH. Overview of issues in the longitudinal
analysis of respiratory data. Am J Respir Crit Care Med
1995;154:S208–11.
28. Kerstjens HAM, Rijcken B, Schouten JP, et al. Decline of FEV1
by age and smoking status: facts, figures, and fallacies.
Thorax 1997;52:820–7.
29. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the
normal maximal expiratory flow-volume curve with growth
and aging. Am Rev Respir Dis 1983;127:725–34.
30. Tager IB, Segal MR, Speizer FE, et al. The natural history of
forced expiratory volumes. Effect of cigarette smoking and
respiratory symptoms. Am Rev Respir Dis 1988;138:837–49.
31. Sherrill DL, Lebowitz MD, Knudson RJ, et al. Smoking and
symptom effects on the curves of lung function growth and
decline. Am Rev Respir Dis 1991;144:17–22.
32. Lazarus R, Sparrow D, Weiss ST. Baseline ventilatory function
predicts the development of higher levels of fasting insulin
and fasting insulin resistance index: the Normative Aging
Study. Eur Respir J 1998;12:641–5.
33. Lazarus R, Sparrow D, Weiss ST. Impaired ventilatory
function and elevated insulin levels in nondiabetic males:
the Normative Aging Study. Eur Respir J 1998;12:635–40.
34. Friedman G, Klatsky A, Siegelaub M. Lung function and risk
of myocardial infaction and sudden cardiac death. N Engl J
Med 1976;294:1071–5.
35. Kannel W, Hubert H, Lew E. Vital capacity as a predictor of
cardiovascular disease: the Framingham study. Am Heart J
1983;105:311–5.
36. Lange P, Nyboe J, Jensen G, et al. Ventilatory function
impairment and risk of cardiovascular death and of fatal or
non-fatal myocardial infarction. Eur Respir J 1991;4:1080–7.
37. Neas LM, Schwartz J. Pulmonary function levels as pre-
dictors of mortality in a national sample of US adults. Am J
Epidemiol 1998;147:1011–8.
38. O’Donnell CP, Tankersley CG, Polotsky VP, et al. Leptin,
obesity, and respiratory function. Respir Physiol
2000;119:173–80.
39. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates
proinflammatory immune responses. FASEB J
1998;12:57–65.
40. Gomez-Ambrosi J, Fru¨beck G. Do resistin and resistin-like
molecules also link obesity to inflammatory diseases? Ann
Internal Med 2001;135:306–7.
41. Holcomb IN, Kabakoff RC, Chan B, et al. FIZZ1, a novel
cysteine-rich secreted protein associated with pulmonary
inflammation, defines a new gene family. EMBO J
2000;19:4046–55.
42. Schouten JP, Tager IB. Interpretation of longitudinal studies.
An overview. Am J Respir Crit Care Med 1996;154:S278–84.
